Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
40.2M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
5.14M
-
Shares change
-
-367K
-
Total reported value, excl. options
-
$12.3M
-
Value change
-
-$1.13M
-
Number of buys
-
7
-
Number of sells
-
-10
-
Price
-
$2.39
Significant Holders of Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) as of Q2 2023
32 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.14M shares
of 40.2M outstanding shares and own 12.76% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.69M shares), ORBIMED ADVISORS LLC (773K shares), VANGUARD GROUP INC (428K shares), Boxer Capital, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), Ikarian Capital, LLC (189K shares), Privium Fund Management (UK) Ltd (120K shares), RENAISSANCE TECHNOLOGIES LLC (83.6K shares), GEODE CAPITAL MANAGEMENT, LLC (83.4K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (64K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.